Literature DB >> 29431183

Transcriptomic definition of molecular subgroups of small round cell sarcomas.

Sarah Watson1,2, Virginie Perrin1,2, Delphine Guillemot3, Stephanie Reynaud3, Jean-Michel Coindre4,5, Marie Karanian6, Jean-Marc Guinebretière7, Paul Freneaux8, François Le Loarer4,5, Megane Bouvet3, Louise Galmiche-Rolland9,10, Frédérique Larousserie11, Elisabeth Longchampt12, Dominique Ranchere-Vince6, Gaelle Pierron3, Olivier Delattre1,2,3,13, Franck Tirode1,2,14.   

Abstract

Sarcoma represents a highly heterogeneous group of tumours. We report here the first unbiased and systematic search for gene fusions combined with unsupervised expression analysis of a series of 184 small round cell sarcomas. Fusion genes were detected in 59% of samples, with half of them being observed recurrently. We identified biologically homogeneous groups of tumours such as the CIC-fused (to DUX4, FOXO4 or NUTM1) and BCOR-rearranged (BCOR-CCNB3, BCOR-MAML3, ZC3H7B-BCOR, and BCOR internal duplication) tumour groups. VGLL2-fused tumours represented a more biologically and pathologically heterogeneous group. This study also refined the characteristics of some entities such as EWSR1-PATZ1 spindle cell sarcoma or FUS-NFATC2 bone tumours that are different from EWSR1-NFATC2 tumours and transcriptionally resemble CIC-fused tumour entities. We also describe a completely novel group of epithelioid and spindle-cell rhabdomyosarcomas characterized by EWSR1- or FUS-TFCP2 fusions. Finally, expression data identified some potentially new therapeutic targets or pathways.
Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  BCOR-rearranged; CIC-fused; EWSR1-PATZ1; FET-TFCP2; FUS-NFATC2; RNAseq; VGLL2-NCOA2; fusion genes; sarcoma

Mesh:

Substances:

Year:  2018        PMID: 29431183     DOI: 10.1002/path.5053

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  59 in total

1.  CIC-NUTM1 fusion: A case which expands the spectrum of NUT-rearranged epithelioid malignancies.

Authors:  Inga-Marie Schaefer; Paola Dal Cin; Latrice M Landry; Christopher D M Fletcher; Glenn J Hanna; Christopher A French
Journal:  Genes Chromosomes Cancer       Date:  2018-08-14       Impact factor: 5.006

2.  The clinical heterogeneity of round cell sarcomas with EWSR1/FUS gene fusions: Impact of gene fusion type on clinical features and outcome.

Authors:  Yusuke Tsuda; Lei Zhang; Paul Meyers; William D Tap; John H Healey; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2020-05-28       Impact factor: 5.006

Review 3.  The current landscape of rhabdomyosarcomas: an update.

Authors:  Julia Leiner; François Le Loarer
Journal:  Virchows Arch       Date:  2019-11-06       Impact factor: 4.064

4.  FET(EWSR1)-TFCP2 Rhabdomyosarcoma: An Additional Example of this Aggressive Variant with Predilection for the Gnathic Bones.

Authors:  Ioannis G Koutlas; Damon R Olson; Jawhar Rawwas
Journal:  Head Neck Pathol       Date:  2020-06-05

5.  Molecular Approaches to Diagnosis in Ewing Sarcoma: Fluorescence In Situ Hybridization (FISH).

Authors:  Marcel Trautmann; Wolfgang Hartmann
Journal:  Methods Mol Biol       Date:  2021

Review 6.  New fusion sarcomas: histopathology and clinical significance of selected entities.

Authors:  Markku Miettinen; Anna Felisiak-Golabek; Alejandro Luiña Contreras; John Glod; Rosandra N Kaplan; Jonathan Keith Killian; Jerzy Lasota
Journal:  Hum Pathol       Date:  2019-01-08       Impact factor: 3.466

7.  CIC-DUX4 oncoprotein drives sarcoma metastasis and tumorigenesis via distinct regulatory programs.

Authors:  Ross A Okimoto; Wei Wu; Shigeki Nanjo; Victor Olivas; Yone K Lin; Rovingaile Kriska Ponce; Rieko Oyama; Tadashi Kondo; Trever G Bivona
Journal:  J Clin Invest       Date:  2019-07-22       Impact factor: 14.808

Review 8.  EWSR1/FUS-NFATc2 rearranged round cell sarcoma: clinicopathological series of 4 cases and literature review.

Authors:  Julio A Diaz-Perez; G Petur Nielsen; Cristina Antonescu; Martin S Taylor; Santiago A Lozano-Calderon; Andrew E Rosenberg
Journal:  Hum Pathol       Date:  2019-05-09       Impact factor: 3.466

Review 9.  [New in the current WHO classification (2020) for soft tissue sarcomas].

Authors:  Eva Wardelmann; Wolfgang Hartmann
Journal:  Pathologe       Date:  2021-04-06       Impact factor: 1.011

10.  NKX3-1 Is a Useful Immunohistochemical Marker of EWSR1-NFATC2 Sarcoma and Mesenchymal Chondrosarcoma.

Authors:  Ken-Ichi Yoshida; Isidro Machado; Toru Motoi; Antonina Parafioriti; Maribel Lacambra; Hitoshi Ichikawa; Akira Kawai; Cristina R Antonescu; Akihiko Yoshida
Journal:  Am J Surg Pathol       Date:  2020-06       Impact factor: 6.394

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.